Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS | Embrace the transformative power of multimodal AI-driven analytics to accelerate innovation and realize the full potential of ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in ...

We are still awaiting a trial called the NILE trial, which is looking at platinum-based chemotherapy plus Imfinzi (durvalumab) and Imjudo (tremelimumab) for advanced disease. That trial also has a ...

Immunotherapy is an area where AZ faces tough competition and its checkpoint inhibitors Imfinzi (durvalumab) and tremelimumab have failed to score the big trial wins seen with Merck & Co's rival ...

To determine the surgical safety after neo-adjuvant durvalumab +/- tremelimumab for patients with locally advanced renal rell carcinoma (RCC) METHODS: An open-label phase 1b trial of neoadjuvant ...

234 PC_BETS—A Biomarker-Selected Phase II Study of Durvalumab and Tremelimumab in Patients with Previously Treated mCRPC Resistant to AR Pathway Inhibitors ASCO 2025: Survival and Hospitalizations ...

Gastric cancer, or stomach cancer, is a type of cancer that begins in the mucus-producing cells on the inside lining of the stomach. The most common type of stomach cancer is adenocarcinoma ...